{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:09:20Z","timestamp":1785470960268,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder forming hamartomas throughout the body. Facial angiofibromas (FAs) occur in 75% of TSC patients, which are often enlarged, impairing the appearance of the face, and reducing the patient\u2019s quality of life (QOL). The aim of this study was to characterize the impact of topical sirolimus treatment on the health-related QOL in patients with FA associated with TSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated a total of 33 patients who received sirolimus gel treatment for FA associated with TSC and assessed the changes in the health-related QOL using the Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey. SF-36 surveys were performed before and after 3 months of treatment. The conditions of the patients after using the sirolimus gel were categorized into the following three categories: \u201cimproved,\u201d \u201cunchanged,\u201d and \u201caggravated.\u201d Adverse events were investigated using the CTCAE v5.0-JCOG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the patients was 25 (range 14\u201355) years. After 3\u2009months of sirolimus gel treatment, three scale scores of the SF-36, vitality (VT), social function (SF), and mental health (MH), were significantly improved compared to before the treatment. The VT and SF in patients who had improved FA were significantly better than those in the other patients. There were no significant differences in any scale scores between patients with and without adverse events at 3 months after the initiation of sirolimus gel treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first report regarding improved health-related quality of life in patients treated with sirolimus gel for FA associated with TSC by using the SF-36. The three scale scores associated with mental health were significantly improved compared to before the treatment. The health-related QOL in patients receiving sirolimus gel treatment is more strongly affected by the treatment efficacy than adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Mini-abstract<\/jats:title>\n                    <jats:p>Sirolimus gel treatment improves the health-related QOL in patients with FA associated with TSC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01417-5","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T12:03:55Z","timestamp":1591099435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex"],"prefix":"10.1186","volume":"15","author":[{"given":"Takashi","family":"Hatano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Moritake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/qjmed\/hcy215","volume":"112","author":"S Amin","year":"2019","unstructured":"Amin S, Kingswood JC, Bolton RF, et al. The UK guidelines for management and surveillance of tuberous sclerosis complex. QJM. 2019;112:171\u201382.","journal-title":"QJM"},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805\u20138.","journal-title":"Science"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"The European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","unstructured":"The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305\u201315.","journal-title":"Cell"},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259\u201368.","journal-title":"Curr Biol"},{"key":"1417_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153:39\u201348.","journal-title":"JAMA Dermatol"},{"key":"1417_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","volume":"154","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical traial. JAMA Dermatol. 2018;154:781\u20138.","journal-title":"JAMA Dermatol"},{"key":"1417_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1037\u201344.","journal-title":"J Clin Epidemiol"},{"key":"1417_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","volume":"26","author":"S Salido","year":"2012","unstructured":"Salido S, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J Eur Acad Dermatol Venereol. 2012;26:1315\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Ware JE Jr, Koshinski M, et al. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1045\u201353.","journal-title":"J Clin Epidemiol"},{"key":"1417_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","volume":"154","author":"MK Koenig","year":"2018","unstructured":"Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex. JAMA dermatology. 2018;154:773\u201380..","journal-title":"JAMA dermatology"},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/pde.12933","volume":"33","author":"C Crall","year":"2016","unstructured":"Crall C, Valle M, Kapur K, Al. Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers. Pediatr Dermatol. 2016;33:518\u201325.","journal-title":"Pediatr Dermatol"},{"key":"1417_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI) \u2014 a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1417_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The children\u2019s dermatology life quality index (DLQI): initial validation and practical use. Br J Dermatol. 1995;132:942\u20139.","journal-title":"Br J Dermatol"},{"key":"1417_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1477-7525-4-46","volume":"4","author":"N Takahashi","year":"2006","unstructured":"Takahashi N, Suzukamo Y, Nakamura M, et al. Japanese version of the dermatology life quality index: validity and reliability in patients with acne. Health Qual Life Outcomes. 2006;4:46.","journal-title":"Health Qual Life Outcomes"},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00005650-198108000-00001","volume":"19","author":"M Bergne","year":"1981","unstructured":"Bergne M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19:787\u2013805.","journal-title":"Med Care"},{"key":"1417_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, et al. The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570\u20139.","journal-title":"J Clin Oncol"},{"key":"1417_CR17","doi-asserted-by":"publisher","first-page":"8404378","DOI":"10.1155\/2017\/8404378","volume":"2017","author":"S Amin","year":"2017","unstructured":"Amin S, Lux A, Khan A, O\u2019callaghan F. (2017) Sirolimus ointment for facial angiofibroma in individuals with tuberous sclerosis complex. Int Sch Res Notices. 2017;2017:8404378. https:\/\/doi.org\/10.1155\/2017\/8404378.","journal-title":"Int Sch Res Notices"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01417-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01417-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01417-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T19:14:12Z","timestamp":1622488452000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01417-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01417-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-20090\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-20090\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of JR Tokyo General Hospital (No. H29\u201327). All patients provided written informed consent before entering the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this article declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}